Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Link to SEPIO compliant JSON-LD document

Variant: NM_000212.2:c.565C>T

CA291224669

812736 (ClinVar)

Gene: ITGB3

Condition: Glanzmann's thrombasthenia

Inheritance Mode: Autosomal recessive inheritance

Link to MONDO

UUID: fd701e2d-bd2e-4499-a8bf-f519215e51f0

HGVS expressions

NM_000212.2:c.565C>T

NC_000017.11:g.47284646C>T

CM000679.2:g.47284646C>T

NC_000017.10:g.45362012C>T

CM000679.1:g.45362012C>T

NC_000017.9:g.42717011C>T

NG_008332.2:g.35805C>T

NM_000212.3:c.565C>T

ENST00000559488.5:c.565C>T

ENST00000560629.1:n.530C>T

ENST00000571680.1:c.565C>T

Pathogenic

PP3 PP1 PP4_Strong PS3_Moderate PM3_Strong PM2_Supporting

Evidence Links 4

Expert Panel

Platelet Disorders VCEP

Criteria Specification Information

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Platelet Disorders VCEP

The NM_000212.2:c.565C>T (p.Pro189Ser) missense variant has been reported in at least three homozygotes and two compound heterozygous probands with phenotypes highly specific to GT (PMIDs: 31565851, 25728920, 24236036, 22250950). The variant has been shown to segregate in at least one family with two affected individuals (PMID: 31565851). This variant is at an extremely low frequency with a MAF of 0.00002638 in the South Asian population of gnomAD and multiple lines of computational evidence support a deleterious effect on the gene /gene product (REVEL score of 0.976). Pro189Ser has been expressed in CHO cells and found to have a 94% reduction in surface expression (PMID: 24236036). In summary, based on the available evidence at this time, the variant is classified as Pathogenic. GT-specific criteria applied: PS3_Moderate, PM2_Supporting, PM3_Strong, PP1, PP3, PP4_Strong.

PP3

SIFT (Damaging), Polyphen2-HDIV 1 (probably Damaging), and Mutation Taster (disease causing) agree that this variant has a deleterious effect and the REVEL score is 0.976, above the >0.7 threshold.

PP1

The proband and affected brother share the compound heterozygous genotype of Pro189Ser and Cys210Ser (PMID: 31565851).

PP4_Strong

At least three probands have been reported with this variant that meet the criteria for PP4; including mucocutaneous bleeding, impaired aggregation with all agonists except ristocetin, and reduced surface expression of αIIbβ3. At least one (PMID: 25728920) meets criteria for PP4_strong as ITGA2B and ITGB3 were sequenced across all exons and intron/exon boundaries.

PubMed:24236036

PubMed:22250950

PS3_Moderate

In PMID: 24236036, the mutation was introduced into a β3 expression construct and transient expression in CHO cells was performed with co-expression of normal human αIIb. There was a 94% reduction in surface expression of the αIIbβ3 receptor in CHO cells expressing P163Sβ3 compared to those expressing WTβ3.

The mutation was introduced into a β3 expression construct and transient expression in CHO cells was performed with co-expression of normal human αIIb. There was a 94% reduction in surface expression of the αIIbβ3 receptor in CHO cells expressing P163Sβ3 compared to those expressing WTβ3, measured by flow cytometry. PubMed:24236036

PM3_Strong

This variant has been reported in two homozygotes and two compound heterozygotes with pathogenic variant c.2113del and likely pathogenic variant Cys210Ser.

PubMed:25728920

PubMed:31565851

PM2_Supporting

This variant is at an extremely low frequency (below the <1/10,000 threshold) with an overall allele frequency from gnomAD of 0.00001193 and MAF of 0.00002638 (3/113,730 alleles) in the South Asian population.

Approved on: 2020-09-06

Published on: 2021-01-28

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.